1 – 9 of 9
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial
(
- Contribution to journal › Article
-
Mark
Modeling normal and malignant hematopoiesis in vitro. To screen for extrinsic regulators and differentiation therapy.
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2015
-
Mark
The applicability of the WHO classification in paediatric AML. A NOPHO-AML study
(
- Contribution to journal › Article
- 2014
-
Mark
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
(
- Contribution to journal › Article
- 2013
-
Mark
Outcome of poor response paediatric AML using early SCT
(
- Contribution to journal › Article
- 2010
-
Mark
Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia
(
- Contribution to journal › Article
- 2009
-
Mark
Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study
(
- Contribution to journal › Article
- 2007
-
Mark
Improved outcome after relapse in children with acute myeloid leukaemia
(
- Contribution to journal › Article
- 2005
-
Mark
Acute leukaemia in children with Down syndrome: a population-based Nordic study
(
- Contribution to journal › Article